Up to 56% reduction in WOMAC pain scores from baseline1
The most common side effects were bruising, numbness, redness, tenderness on palpation, and swelling.
Study Design: Randomized, double-blind, sham-controlled, multicenter trial with a 6-month follow-up in patients with knee OA. Patients were randomized 2:1 to cryoneurolysis targeting the infrapatellar branch of the saphenous nerve (ISN) or sham treatment (N=180; 121 in active group, 59 received sham).1
Treatment with iovera° helped patients get moving1*
- Significant improvements in physical function demonstrated at Day 30 (P=0.001), Day 60 (P=0.04), and Day 90 (P=0.017)
- Significant reduction in stiffness at Day 90 (P=0.03)
Radnovich as a
AAOS=American Academy of Orthopaedic Surgeons; CPG=clinical practice guidelines; ISN=infrapatellar branch of the saphenous nerve; OA=osteoarthritis; TKA= total knee arthroplasty; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index.
*iovera° therapy does not treat the underlying cause of the pain; timely remediation is necessary to address the root cause.
Reference: 1. Radnovich R et al. Osteoarthritis Cartilage. 2017;25(8):1247-1256.